HYPERBOOST
Financiado
Creation of advanced cancer treatment planning to boost the effect of Radiothera...
Creation of advanced cancer treatment planning to boost the effect of Radiotherapy by combining with hyperthermia heating the tumor.
Hyperthermia (HT), heating tumors to temperatures of 40-44°C, is an oncological treatment used in combination with
radiotherapy (RT) and chemotherapy to enhance their efficacy. Clinical effectiveness of HT has been demonstrated in...
Hyperthermia (HT), heating tumors to temperatures of 40-44°C, is an oncological treatment used in combination with
radiotherapy (RT) and chemotherapy to enhance their efficacy. Clinical effectiveness of HT has been demonstrated in
randomised studies and HT is currently applied for many clinical indications, like cervical cancer and recurrent breast cancer.
Clinical results can be further improved as application of HT with well-controlled tumor temperatures and optimal timing and
sequence realising full synergy of RT+HT is challenging. Optimal HT delivery requires accurate planning, moreover
preclinical research has shown that many mechanisms are responsible for the therapeutic effect of HT, all presumably with a
different temperature-effect relationship and with different optimal timing between RT and HT. Optimisation of clinical RT+HT
treatments therefore requires a quantum leap in understanding and in clinical application.
Scientific objective of this multidisciplinary project with contributions from all sectors and disciplines (biology, physics and
oncology) is to combine training and research into the synergistic molecular mechanisms responsible for the therapeutic
effect of HT on RT with the development of a versatile and innovative planning platform which utilises biological knowledge
to achieve optimal patient-specific treatment delivery and ultimately application in a clinical registration study in a network of
European centres implementing this treatment planning software to ensure optimal treatment delivery.
This ground-breaking and multidisciplinary project with contributions from biology, physics and oncology will create a
versatile and innovative planning platform, enhance fundamental knowledge and create practical tools to achieve
personalised treatment, thereby augmenting treatment delivery and clinical results. The projects will also educate 15 highly
skilled professionals capable of addressing and solving complex oncological issues.
ver más
Duración del proyecto: 51 meses
Fecha Inicio: 2020-08-13
Fecha Fin: 2024-11-30
Fecha Fin: 2024-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-08-13
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-ITN-2020:
Innovative Training Networks
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
STICHTING AMSTERDAM UMC
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
196.58K€ |
Participante
252.79K€ |
Participante